A Randomized Phase II Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for Newly Diagnosed Older Adults with IDH2 Mutant Acute Myeloid Leukemia: A MyeloMATCH Substudy

Protocol No
SWOG-MM1OA-S03
Staff Member
Guru Subramanian Guru Murthy
Phase
II
Summary

This study is being done to answer the following questions:
1. Is adding the drug enasidenib to treatment that uses ASTX727 and venetoclax safe for participants?
2. Can adding the drug enasidenib to treatment that uses ASTX727 and venetoclax help patients get rid of more AML? Enasidenib is an oral targeted therapy that is approved by the Food and Drug Administration (FDA) to treat AML that has an IDH2 mutation.
Objective
Study comparing new treatments for newly diagnosed AML with IDH2 gene change
Status
OPEN TO ACCRUAL
Categories
Cancer, Multiple Myeloma, Leukemia, Hematologic/Blood Related Cancers
ClinicalTrials.gov
https://www.clinicaltrials.gov/study/NCT06672146